Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01547806 · OUTCOME

Percentage of Patients That Required Plerixafor + Granulocyte-colony Stimulating Factor (G-CSF) And Only G-CSF (no Plerixafor)

Collection of Transplant Stem Cells for Plasma Cell Myeloma · Source last updated 2018-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
Not reported
Time frame
One week of mobilization therapy

What was measured

Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all

Groups in this outcome

Hematopoietic Progenitor Cells

Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols. Filgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days Plerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight Apheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Hematopoietic Progenitor Cells49

Reported measurements

Plerixafor + G-CSF
Values in percentage of patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Hematopoietic Progenitor Cells47Not reportedNot reportedNot reportedNot reported
Only G-CSF (no plerixafor)
Values in percentage of patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Hematopoietic Progenitor Cells53Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        47
    title
    Plerixafor + G-CSF
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        53
    title
    Only G-CSF (no plerixafor)
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all
groups
  1. description
    Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols. Filgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days Plerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight Apheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
    id
    OG000
    title
    Hematopoietic Progenitor Cells
param Type
NUMBER
reporting Status
POSTED
time Frame
One week of mobilization therapy
title
Percentage of Patients That Required Plerixafor + Granulocyte-colony Stimulating Factor (G-CSF) And Only G-CSF (no Plerixafor)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice